好色先生

好色先生

Explore the latest content from across our publications

Log In

Forgot Password?
Create New Account

Loading... please wait

Abstract Details

Incidence and Recurrence of Ischemic Stroke in a Large Midwestern Healthcare System
Cerebrovascular Disease and Interventional Neurology
P8 - Poster Session 8 (11:45 AM-12:45 PM)
5-016
Determine time trends in non-cardioembolic ischemic stroke (IS) incidence and recurrent IS among patients in a Midwestern healthcare system.

IS is a leading cause of death and disability in the US. Contemporary trends in incidence (reflecting primary prevention) and recurrence (reflecting secondary prevention) are not well described but are critical to guide strategies that reduce stroke burden.

We conducted a retrospective cohort study using electronic health record data from an integrated healthcare system in Wisconsin and Illinois. Adults (≥18 years) with an emergency department or inpatient admission for IS (ICD-10) and no prior atrial fibrillation were included. One-year recurrent IS was defined as a hospitalization for a second stroke within 1 year of index discharge (21-day washout period to exclude index stroke re-admissions). Age-adjusted incidence rates/100 person-years (PY) and 1-year recurrence/100 PY were calculated for 2015–2023 in Wisconsin and 2021–2023 in Illinois.

Among 16,503 patients with IS (Wisconsin n=10,246; Illinois n=6,257), mean (±standard deviation) age was 68.5±14.1 years, 51.2% were male, and 68.4% were non-Hispanic White. In Wisconsin (2015−2023), incidence significantly increased from 0.43 to 0.52/100 PY (absolute difference [AD] 0.09, 95% confidence interval [CI] 0.05−0.13). In Illinois (2021–2023), incidence stayed high, remaining at ~0.70/100 PY (AD 0.04, 95% CI 0.01–0.09). One-year IS recurrence showed no notable change: Wisconsin, 15.41/100 PY in 2015 to 17.71/100 PY in 2023 (AD 2.30, 95% CI –1.03−5.63); Illinois, 13.64/100 PY in 2021 to 11.85/100 PY in 2023 (AD 1.79, 95% CI –0.49−4.07).

In Wisconsin, the rising incidence of IS suggests gaps in primary prevention. Stable recurrence indicates treatment and secondary prevention have not worsened, though improvement is needed. In Illinois, incidence and recurrence remain high with no notable change, though data are limited to 3 years. Strategies including risk-factor evaluation are needed to strengthen prevention and management of IS.

Authors/Disclosures
Emily Durden, PhD
PRESENTER
Dr. Durden has received personal compensation for serving as an employee of Bayer Healthcare Pharmaceuticals Inc..
Nicole Glowacki, MPH Miss Glowacki has nothing to disclose.
Joseph Chase Mr. Chase has received personal compensation for serving as an employee of Advocate Aurora Health.
Gilbert Ko, PharmD, MBA, MS Mr. Ko has received personal compensation for serving as an employee of Bayer. Mr. Ko has received personal compensation for serving as an employee of Johnson & Johnson.
Ryan Farej Mr. Farej has received personal compensation for serving as an employee of Bayer.
Lawrence E. Fried, MD (Children's Hospital of Philadelphia, Child Neurology) Dr. Fried has received personal compensation for serving as an employee of Bayer Pharmaceuticals. Dr. Fried has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Virpax Pharmaceuticals. Dr. Fried has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Guidepoint Global. Dr. Fried has stock in Bayer. Dr. Fried has stock in Horus. The institution of Dr. Fried has received research support from Health Resources & Services Administration of the United States Department of Health and Human Services.
Mamta Jaiswal, MBBS, PhD Dr. Jaiswal has nothing to disclose.
Sarang Baman, MD Dr. Baman has nothing to disclose.
Rasha Khatib, PhD Dr. Khatib has nothing to disclose.